title: The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS.
abstract: BACKGROUND
  After the resolution of contrast enhancement, the majority of new MS lesions become isointense with surrounding white matter on T1-weighted MRI. Less commonly, a hypointense T1 lesion develops, representing the development of more severe focal tissue damage. Interferon beta (IFNbeta) reduces both the number of new enhancing lesions and the duration of contrast enhancement.
  
  
  OBJECTIVE
  To determine if IFNbeta affects the degree of tissue damage within new lesions and if its effects are related to lesion size.
  
  
  METHODS
  One hundred twenty-five patients with secondary progressive MS from seven European sites were randomized to receive either IFNbeta-1b or placebo. Monthly, contrast-enhanced T1-weighted MR images were acquired at baseline, at months 1 to 6, and at months 19 to 24. The size of all new enhancing lesions developing between months 1 and 6 was recorded and their appearance at follow-up documented.
  
  
  RESULTS
  In the first 6 months, fewer new enhancing lesions occurred in the IFNbeta-1b arm. This difference was greater for small (70% decrease) than for large (46% decrease) lesions. Hypointense T1 lesions were more likely to form from large (25%) than from small (9%) enhancing lesions in both treatment arms. Patients taking IFNbeta-1b developed fewer hypointense T1 lesions; however, the proportion of enhancing lesions developing into hypointense T1 lesions was similar in both arms.
  
  
  CONCLUSIONS
  IFNbeta-1b reduced the number of new enhancing lesions, with a greater effect on small lesions. However, when a new enhancing lesion did become established, treatment with IFNbeta-1b did not alter its subsequent course.
authors.affiliation: NMR Research Unit, Institute of Neurology, University College London, UK.
authors.forename: P A
authors.initials: PA
authors.lastname: Brex
authors.forename: P D
authors.initials: PD
authors.lastname: Molyneux
authors.forename: P
authors.initials: P
authors.lastname: Smiddy
authors.forename: F
authors.initials: F
authors.lastname: Barkhof
authors.forename: M
authors.initials: M
authors.lastname: Filippi
authors.forename: T A
authors.initials: TA
authors.lastname: Yousry
authors.forename: D
authors.initials: D
authors.lastname: Hahn
authors.forename: Y
authors.initials: Y
authors.lastname: Rolland
authors.forename: O
authors.initials: O
authors.lastname: Salonen
authors.forename: C
authors.initials: C
authors.lastname: Pozzilli
authors.forename: C H
authors.initials: CH
authors.lastname: Polman
authors.forename: A J
authors.initials: AJ
authors.lastname: Thompson
authors.forename: L
authors.initials: L
authors.lastname: Kappos
authors.forename: D H
authors.initials: DH
authors.lastname: Miller
mesh_terms: D000328:Adult; D001921:Brain / Q000187:drug effects* / Q000473:pathology*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D000068576:Interferon beta-1b; D016899:Interferon-beta